As we remain steadfast in our long-range mission of being the voice for the ovarian cancer community and funding life-saving research, we also want to acknowledge the moment we are in now. We know that the isolation required of all of us may be both familiar to those who are undergoing or have gone through … Continued
(3/17/2020) Research out of the University of Bristol looked at genes and how they inhibit an enzyme involved in regulating the body’s cholesterol. This enzyme is the target of statin drugs, which are prescribed to lower cholesterol levels. The study involved 63,347 women between 20 and 100 years old, of whom 22,406 had ovarian cancer. … Continued
She has swum in the Amazon, gone ice fishing in the Arctic, traveled the Galapagos, and hang-glided in New Zealand. But the biggest trail Dr. Beth Karlan has blazed throughout her life has been in the field of gynecologic oncology. Dr. Karlan is Professor and Vice Chair of Women’s Health Research in the Department of … Continued
(March 13, 2020) As a global charity, we recognize the extraordinarily stressful times we as a society are all in together. We have taken every precaution to protect OCRA staff as they continue to do their jobs (remotely) in our collective fight against ovarian cancer. And if you have ovarian cancer and are concerned about … Continued
The ovarian cancer landscape is ever evolving, and it can be challenging to keep up with new research discoveries and what they could mean for you. At OCRA’s National Conference, you can learn the latest updates about the topics most important to you, straight from leaders in the field. Don’t miss this opportunity to empower … Continued
Stacy Saravo, like anyone who’s been given a terrible diagnosis, has received her share of well-meaning but dumb advice. (“Eat lemons! They’ll cure cancer.”) But there’s one moment that takes the cake. She was undergoing chemotherapy, feeling uncomfortable, had no eyebrows, and her immune system was low … yet she decided to go to the … Continued
Dr. Ron Buckanovich, an OCRA grantee, uses a metaphor to describe his work. “If I’m trying to get into Chicago and the highways that get me into the city are blocked off, no matter how important my job is, I’m not going to get there.” He’s talking about immunotherapy and the fact that the cells … Continued
Jamie Davey is an open book. She will tell you about her ‘buns and guns’ class at the gym, how you can best support friends and loved ones facing ovarian cancer, and what it’s like being a 28-year-old in menopause. Jamie lives in Trumbull County, Ohio and was 26 years old when she was diagnosed. … Continued
What do the fur patterns of tigers have to do with advances in ovarian cancer treatment? Juan Cubillos-Ruiz, PhD, an OCRA grantee, grew up on a farm near Bogota, Colombia. He spent his younger years looking at the world around him, questioning everything. Why was corn white, yellow or purple? Why did foods vary in … Continued
“Be present and embrace the suck.” This is Andrew Simone’s personal mantra. It’s what got him through a nearly 2000-mile, 47-day bike ride from Vancouver, British Columbia to Tijuana, Mexico in 2018. And a “short loop” (500 miles) around the Olympic National Forest in Washington State in 2019. It’s what will get him through a … Continued
Are you an ovarian cancer survivor, patient, or caregiver? Don’t miss YOUR chance to learn what’s new in ovarian cancer treatments and research, and to meet others in the ovarian cancer community. Early Bird Registration is open! OCRA’s Ovarian Cancer National Conference® brings together people from across the country for a weekend of informative presentations, … Continued
(February 13, 2020) PARP inhibitors have shown to be a promising treatment option for a subset of ovarian cancer patients. As of February 2020, there are currently 3 FDA-approved PARP inhibitors for ovarian cancer: olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). In an interview with OncLive, Dr. Robert Coleman, a member of OCRA’s Scientific Advisory … Continued
Get email updates about research news, action alerts, and ways to join the fight.
